首页> 美国卫生研究院文献>Frontiers in Neurology >Long-Term Effect of GPi-DBS in a Patient With Generalized Dystonia Due to GLUT1 Deficiency Syndrome
【2h】

Long-Term Effect of GPi-DBS in a Patient With Generalized Dystonia Due to GLUT1 Deficiency Syndrome

机译:GPi-DBS对由于GLUT1缺乏综合症而引起的广泛性肌张力障碍患者的长期疗效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Treatment outcomes from pallidal deep brain stimulation are highly heterogeneous reflecting the phenotypic and etiologic spectrum of dystonia. Treatment stratification to neurostimulation therapy primarily relies on the phenotypic motor presentation; however, etiology including genetic factors are increasingly recognized as modifiers of treatment outcomes. Here, we describe a 53 year-old female patient with a progressive generalized dystonia since age 25. The patient underwent deep brain stimulation of the globus pallidus internus (GPi-DBS) at age 44. Since the clinical phenotype included mobile choreo-dystonic features, we expected favorable therapeutic outcome from GPi-DBS. Although mobile dystonia components were slightly improved in the long-term outcome from GPi-DBS the overall therapeutic response 9 years from implantation was limited when comparing “stimulation off” and “stimulation on” despite of proper electrode localization and sufficient stimulation programming. In order to further understand the reason for this limited motor symptom response, we aimed to clarify the etiology of generalized dystonia in this patient. Genetic testing identified a novel heterozygous pathogenic SLC2A1 mutation as cause of glucose transporter type 1 deficiency syndrome (GLUT1-DS). This case report presents the first outcome of GPi-DBS in a patient with GLUT1-DS, and suggests that genotype relations may increasingly complement phenotype-based therapy stratification of GPi-DBS in dystonia.
机译:苍白球深部脑刺激的治疗结果高度异质,反映了肌张力障碍的表型和病因谱。神经刺激治疗的治疗分层主要取决于表型运动表现。然而,包括遗传因素在内的病因越来越多地被认为是治疗结果的改良剂。在这里,我们描述了一名53岁的女性患者,该患者从25岁开始就患有进行性肌张力障碍。该患者在44岁时接受了苍白球内翻(GPi-DBS)的深部脑刺激。 ,我们预期GPi-DBS会产生良好的治疗效果。尽管GPi-DBS的长期结果可移动性肌张力障碍组件略有改善,但是尽管比较合适的电极定位和足够的刺激程序,但在比较“关闭刺激”和“开启刺激”时,植入后9年的总体治疗反应有限。为了进一步了解这种运动症状反应受限的原因,我们旨在阐明该患者普遍性肌张力障碍的病因。遗传学测试确定了一种新的杂合病原性SLC2A1突变是1型葡萄糖转运蛋白缺乏症(GLUT1-DS)的原因。该病例报告介绍了GLUT1-DS患者中GPi-DBS的第一个结局,并表明基因型关系可能越来越多地补充肌张力障碍中GPi-DBS的基于表型的治疗分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号